This makes the PAB model ideal to study RV remodeling due to PAH and potential benefits of therapeutic interventions, separate from alterations in pulmonary vascular resistance (PVR) or VEGF inhibition. The gene discussed is VEGFA; the disease is pulmonary arterial hypertension.